AIM ImmunoTech News - September 2026

🟢 AIM ImmunoTech is trading 8.35% up today after European Ampligen patent protection through 2041

AIM ImmunoTech is trading at $0.25 (+8.35%) after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment through June...

🟢 AIM ImmunoTech is trading 17.52% up in pre-market after broad U.S. patent covering Ampligen and pembrolizumab

AIM ImmunoTech is trading at $0.27, up 17.52% in pre-market trading on September 1, 2026, after announcing a broad U.S. patent for Ampligen combined with...